Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
14.09B | 14.20B | 15.80B | 14.84B | 10.16B | Gross Profit |
2.65B | 2.57B | 3.10B | 2.85B | 1.91B | EBIT |
546.00M | 1.16B | 781.00M | 635.00M | 87.00M | EBITDA |
1.30B | 1.67B | 1.64B | 1.69B | 1.58B | Net Income Common Stockholders |
338.00M | 625.00M | 944.00M | 537.00M | 500.00M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
2.09B | 1.53B | 1.34B | 1.84B | 1.65B | Total Assets |
13.99B | 14.45B | 16.99B | 16.57B | 16.03B | Total Debt |
4.16B | 3.93B | 4.23B | 4.33B | 3.79B | Net Debt |
2.07B | 2.40B | 2.89B | 2.49B | 2.14B | Total Liabilities |
8.29B | 8.39B | 9.49B | 9.31B | 9.28B | Stockholders Equity |
5.53B | 5.83B | 7.22B | 6.95B | 6.46B |
Cash Flow | Free Cash Flow | |||
729.00M | 565.00M | 846.00M | 638.00M | 723.00M | Operating Cash Flow |
1.38B | 1.40B | 1.57B | 1.31B | 1.22B | Investing Cash Flow |
42.00M | -593.00M | -1.42B | -1.40B | -906.00M | Financing Cash Flow |
-167.00M | -521.00M | -567.00M | 286.00M | 437.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | $508.55M | 3.26 | 10.53% | 9.15% | -9.61% | -43.91% | |
69 Neutral | $11.00B | 6.97 | 17.57% | ― | -1.69% | -33.56% | |
69 Neutral | $4.52B | 9.52 | 10.81% | 3.64% | -0.70% | -7.27% | |
65 Neutral | $5.75B | 17.42 | 6.46% | 1.56% | -11.11% | -46.32% | |
64 Neutral | $441.38M | 12.97 | 5.79% | ― | 0.75% | ― | |
60 Neutral | $6.85B | 11.57 | 3.09% | 4.18% | 2.37% | -21.38% | |
59 Neutral | $1.90B | ― | -3.92% | 3.06% | -2.57% | -248.28% |
On February 5, 2025, BorgWarner’s Board declared a quarterly dividend of $0.11 per share, payable on March 17, 2025. BorgWarner reported its 2024 financial results, highlighting a decrease in net sales and earnings but maintaining a strong cash flow. The company secured new business awards, expecting continued sales growth and a stable operating margin in 2025 despite market challenges.